Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors
Open accessAbstract
The tetracycline antibiotic minocycline beneficially affects neuronal functioning and also inhibits the enzyme 5-lipoxygenase (5-LOX). We hypothesized that similar to 5-LOX inhibitors, minocycline may increase phosphorylation and membrane insertion of the glutamate receptor GluR1. The experiments were performed in primary cultures of mouse striatal neurons and in the prefrontal cortex and striatum of minocycline-treated mice. In vitro, low micromolar minocycline concentrations increased GluR1 phosphorylation at Ser845 and Ser831 and increased the surface content of GluR1. Minocycline also increased GluR1 phosphorylation in vivo. Increased GluR1 phosphorylation and minocycline treatment have been associated with antidepressant and memory-enhancing activities. Direct consequences of minocycline-increased GluR1 phosphorylation are yet to be established.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Minocycline treatment in young mice lowers MMP9 levels.
“and lowered MMP9 levels.”
From Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics (2012) · cites this paper as [124]
In young mice, minocycline raises GluR1 phosphorylation and promotes subsequent AMPA receptor membrane insertion.
“Treatment of young mice with minocycline, a broad-spectrum antibiotic, had a dual effect: increased phosphorylation of GluR1 and subsequent membrane insertion of AMPA receptors (124)”
From Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics (2012) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006 · see citing works
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894 · see citing works
Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789 · see citing works
Oh, M. C., Derkach, V. A., Guire, E. S., & Soderling, T. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509677200 · Cited by 456 · see citing works
Choi, Y., Kim, H., Shin, K. Y., Kim, E., Kim, M., Kim, H.-S., Park, C. H., Jeong, Y. H., Yoo, J., Lee, J., et al. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301377 · Cited by 290 · see citing works
Boudreau, A. C., Reimers, J. M., Milovanovic, M., & Wolf, M. E. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.2163-07.2007 · Cited by 277 · see citing works
Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations
Alano, C. C., Kauppinen, T. M., Valls, A. V., & Swanson, R. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600554103 · Cited by 229 · see citing works
Lin, S., Zhang, Y., Dodel, R. C., Farlow, M. R., Paul, S. M., & Du, Y. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02324-2 · Cited by 126 · see citing works
Chapter 9 The role of the GluR-A (GluR1) AMPA receptor subunit in learning and memory
Sanderson, D. J., Good, M. A., Seeburg, P. H., Sprengel, R., Rawlins, J. N. P., & Bannerman, D. M. (2008) · Progress in brain research · doi:10.1016/s0079-6123(07)00009-x · Cited by 123 · see citing works
Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection
Fagan, S. C., Edwards, D. J., Borlongan, C. V., Xu, L., Arora, A., Feuerstein, G., & Hess, D. C. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2003.12.006 · Cited by 117 · see citing works
Antidepressant-like actions of minocycline combined with several glutamate antagonists
Molina-Hernández, M., Téllez-Alcántara, N. P., Pérez-García, J., Olivera-Lopez, J. I., & Jaramillo, M. T. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.09.004 · Cited by 115 · see citing works
Gonzalez, J., Egea, J., Godino, M. D. C., Fernández-Gómez, F.-J., Sánchez‐Prieto, J., Gandı́a, L., Garcı́a, A. G., Jordán, J., & Hernández-Guijo, J. M. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05873.x · Cited by 111 · see citing works
Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice
Mizoguchi, H., Takuma, K., Fukakusa, A., Ito, Y., Nakatani, A., Ibi, D., Kim, H., & Yamada, K. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0955-0 · Cited by 92 · see citing works
Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation
Song, Y., Wei, E.-Q., Zhang, W.-P., Zhang, L., Liu, J., & Chen, Z. (2004) · Neuroreport · doi:10.1097/00001756-200410050-00007 · Cited by 73 · see citing works
Chu, L., Fang, S., Zhou, Y., Guo-liang, Y. U., Wang, M., ZHANG, W.-P., & Wei, E. (2007) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2007.00578.x · Cited by 71 · see citing works
Archibald, K., Perry, M. J., Molnár, E., & Henley, J. M. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00135-x · Cited by 64 · see citing works
Possible antidepressant effect of minocycline
Levine, J. S., Cholestoy, A., & Zimmerman, J. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.582b · Cited by 60 · see citing works
Empson, R. M., Buckby, L. E., Kraus, M., Bates, K. J., Crompton, M. R., Gundelfinger, E. D., & Beesley, P. W. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04123.x · Cited by 53 · see citing works
Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation
Song, Y., Wei, E.-Q., Zhang, W.-P., Ge, Q., Liu, J., Wang, M., Huang, X.-J., Hu, X., & Chen, Z. (2006) · Brain Research · doi:10.1016/j.brainres.2006.02.042 · Cited by 52 · see citing works
Crombag, H. S., Sutton, J. M., Takamiya, K., Holland, P. C., Gallagher, M., & Huganir, R. L. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06299.x · Cited by 33 · see citing works
Imbesi, M., Zavoreo, I., Uz, T., Sharma, R. P., Dimitrijević, N., Manev, H., & Manev, R. M. (2007) · Brain Research · doi:10.1016/j.brainres.2007.02.012 · Cited by 17 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Pathological pain and the neuroimmune interface
Grace, P. M., Hutchinson, M. R., Maier, S. F., & Watkins, L. R. (2014) · Nature reviews. Immunology · doi:10.1038/nri3621 · Cited by 951 · see citing works
Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics
Bagni, C., Tassone, F., Neri, G., & Hagerman, R. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63141 · Cited by 321 · see citing works
Reinhard, S. M., Razak, K., & Ethell, I. M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00280 · Cited by 219 · see citing works
Novel therapeutic targets in depression: Minocycline as a candidate treatment
Soczynska, J. K., Mansur, R. B., Brietzke, E. M., Swardfager, W., Kennedy, S. H., Woldeyohannes, H. O., Powell, A. M., Manierka, M. S., & McIntyre, R. S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.07.026 · Cited by 190 · see citing works
What is behind the non-antibiotic properties of minocycline?
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.10.006 · Cited by 158 · see citing works
Liu, F., Guo, X., Wu, R., Ou, J., Zheng, Y., Zhang, B., Xie, L., Zhang, L., Yang, L., Yang, S., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.01.011 · Cited by 135 · see citing works
Rotschafer, S. E., Trujillo, M. S., Dansie, L. E., Ethell, I. M., & Razak, K. A. (2012) · Brain Research · doi:10.1016/j.brainres.2011.12.041 · Cited by 130 · see citing works
Utari, A., Chonchaiya, W., Rivera, S. M., Schneider, A., Hagerman, R. J., Faradz, S. M. H., Ethell, I. M., & Nguyen, D. V. (2010) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-115.5.433 · Cited by 105 · see citing works
Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms
Kelly, D. L., Sullivan, K. M., McEvoy, J. P., McMahon, R. P., Wehring, H. J., Gold, J. M., Liu, F., Warfel, D. T., Vyas, G. R., Richardson, C. M., et al. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000345 · Cited by 102 · see citing works
Iwata, Y., Nakajima, S., Suzuki, T., Keefe, R. S. E., Plitman, E., Chung, J. K., Caravaggio, F., Mimura, M., Graff‐Guerrero, A., & Uchida, H. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.68 · Cited by 89 · see citing works
Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans
Sofuoglu, M., Mooney, M. E., Kosten, T. R., Waters, A. J., & Hashimoto, K. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2014-5 · Cited by 70 · see citing works
Minocycline affects cocaine sensitization in mice
Chen, H., Uz, T., & Manev, H. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.01.078 · Cited by 49 · see citing works
Self-citationVolk, D. W. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.019 · Cited by 47 · see citing works
Gipson, T., & Johnston, M. V. (2012) · Neural Plasticity · doi:10.1155/2012/486402 · Cited by 44 · see citing works
Liaury, K., Miyaoka, T., Tsumori, T., Furuya, M., Hashioka, S., Wake, R., Tsuchie, K., Fukushima, M., Limoa, E., Tanra, A. J., et al. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.12.017 · Cited by 40 · see citing works
The Search for an Effective Therapy to Treat Fragile X Syndrome: Dream or Reality?
Castagnola, S., Bardoni, B., & Maurin, T. (2017) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2017.00015 · Cited by 40 · see citing works
Schwaller, F., Beggs, S., & Walker, S. M. (2015) · Anesthesiology · doi:10.1097/aln.0000000000000659 · Cited by 39 · see citing works
da Silva, M. C. M., Gomes, G. F., Fernandes, H. D. B., Silva, A. M., Teixeira, A. L., Moreira, F. A., de Miranda, A. S., & de Oliveira, A. C. P. (2021) · Scientific Reports · doi:10.1038/s41598-021-95059-7 · Cited by 36 · see citing works
Cruz, S. L., Armenta-Reséndiz, M., Carranza‐Aguilar, C. J., & Galván, E. J. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.114980 · Cited by 28 · see citing works
Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes
Wang, H., Pati, S. B. B., Pozzo‐Miller, L. D., & Doering, L. C. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00055 · Cited by 25 · see citing works
Differential contribution of lipoxygenase isozymes to nigrostriatal vulnerability
Chou, V., Holman, T. R., & Manning-Bog, A. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.10.009 · Cited by 24 · see citing works
Buonaguro, E. F., Tomasetti, C., Chiodini, P., Marmo, F., Latte, G., Rossi, R., Avvisati, L., Iasevoli, F., & de Bartolomeis, A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116658987 · Cited by 21 · see citing works
The Ampa Receptor as a Therapeutic Target: Current Perspectives and Emerging Possibilities
Mellor, I. R. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.27 · Cited by 19 · see citing works
Gajbhiye, S. V., Tripathi, R. K., Salve, B., Petare, A. U., & Potey, A. V. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.04.007 · Cited by 19 · see citing works
Chen, H., & Manev, H. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.09.006 · Cited by 15 · see citing works
Self-citationVialko, A., Chałupnik, P., & Szymańska, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136450 · Cited by 14 · see citing works
Minocycline, schizophrenia and GluR1 glutamate receptors
Manev, R. M., & Manev, H. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.11.004 · Cited by 13 · see citing works
Self-citationManev, H., & Manev, R. M. (2009) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482960802702288 · Cited by 11 · see citing works
Self-citationPossible Role of Platelet GluR1 Receptors in Comorbid Depression and Cardiovascular Disease
Chen, H. (2009) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2009/424728 · Cited by 7 · see citing works
Jin, L., Schlesinger, F., Guan, Q., Song, Y., & Nie, Z. (2012) · Pharmacology · doi:10.1159/000336773 · Cited by 7 · see citing works
Reply to: Minocycline, schizophrenia and GluR1 glutamate receptors
Hashimoto, K. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.11.003 · Cited by 2 · see citing works
Marcatili, M., Borgonovo, R., Cimminiello, N., Cornaggia, R. D., Casati, G., Pellicioli, C., Maggioni, L., Motta, F. L., Chiara, R., Ledda, L., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091524 · Cited by 1 · see citing works
Dissecting the role of calcium signaling in Fragile X syndrome
Castagnola, S. (2019) · theses.fr (ABES) · doi:10.70675/3d35096bz79d0z46edz8a70zb783a8f60257
- Authors
- Imbesi, M., Uz, T., Manev, R., Sharma, R. P., & Manev, H.
- Affiliations
- University of Illinois Chicago (US)
- Corresponding author
- Manev, Hari
- ORCID
- Sharma, Rajiv P.
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 2008-12
- Volume
- 447
- Issue
- 2-3
- Pages
- 134-137
- ISSN
- 0304-3940 (ISSN-L)
- PMC
- PMC2604812
- OpenAlex
- W2034705334
- Cited by
- 34
- References
- 21
- Citations by year
- 2025: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2017: 2 · 2016: 2 · 2015: 5 · 2014: 3 · 2012: 6
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neuroscience Letters (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5r21da024099-02)
- National Institute of Mental Health (MH-069839, K01MH069839)
- National Institute on Drug Abuse (1R21 DA024099-01, R21 DA024099)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- minocycline, GluR1, AMPA receptors, receptor phosphorylation, membrane insertion, 5-lipoxygenase inhibition, tetracycline antibiotics, striatal neurons, prefrontal cortex, antidepressant effects, memory enhancement
- MeSH terms
- Analysis of Variance, Animals, Brain, Cells, Cultured, Dose-Response Relationship, Drug, Embryo, Mammalian, Male, Mice, Inbred C57BL, Minocycline, Neurons, Phosphorylation, Serine, Lipoxygenase Inhibitors, Receptors, AMPA, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
